Ticker > Company >

Evonile Pharma share price

Evonile Pharma Ltd.

  43.11 K   45   7 NSE: NOVARTIND BSE: 500672 SECTOR: Trading

1520.40
-69.20 (-4.35%)
NSE: 13 Nov 04:12 PM

Price Summary

Today's High

₹ 1594.8

Today's Low

₹ 1501.4

52 Week High

₹ 2178.46

52 Week Low

₹ 799.42

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 5318.15 Cr.

Enterprise Value

₹ 4650.45 Cr.

No. of Shares

3.5 Cr.

P/E

0

P/B

3.21

Face Value

₹ 5

Div. Yield

0 %

Book Value (TTM)

₹  473.57

CASH

₹ 667.7 Cr.

DEBT

₹ 0 Cr.

Promoter Holding

70.68 %

EPS (TTM)

₹  -1.14

Sales Growth

-0.54%

ROE

11.63 %

ROCE

16.34%

Profit Growth

-7.65 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-0.54%
3 Year-2.2%
5 Year-1.46%

Profit Growth

1 Year-7.65%
3 Year-3.4%
5 Year34.85%

ROE%

1 Year11.63%
3 Year12.01%
5 Year9.91%

ROCE %

1 Year16.34%
3 Year16.61%
5 Year13.19%

Debt/Equity

0

Price to Cash Flow

113.81

Interest Cover Ratio

103.9048

CFO/PAT (5 Yr. Avg.)

0.839698081338577

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Sep 2026 70.68 0.00
Jun 2026 70.68 0.00
Mar 2026 70.68 0.00
Dec 2025 70.68 0.00
Sep 2025 70.68 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 103.9048.
  • The company has an efficient Cash Conversion Cycle of -14.5427 days.
  • Company has a healthy liquidity position with current ratio of 2.4474.
  • The company has a high promoter holding of 70.68%.

 Limitations

  • The company has shown a poor profit growth of -3.39712125575105% for the Past 3 years.
  • The company has shown a poor revenue growth of -2.19621110532456% for the Past 3 years.
  • Company has contingent liabilities of 387.55 Cr.
  • The company is trading at a high EV/EBITDA of 73.2769.

Quarterly Result (All Figures in Cr.)

PARTICULARS Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Net Sales 90.33 85.9 90.55 103.81 56.05
Total Expenditure 66.45 63.54 69.93 68.9 87.87
Operating Profit 23.88 22.36 20.62 34.91 -31.82
Other Income 9.4 8.75 10.01 8.74 7.74
Interest 0.11 0.98 0.07 0.06 4.83
Depreciation 0.52 0.48 0.42 0.42 3.89
Exceptional Items 0 0 0 0 -68.26
Profit Before Tax 32.65 29.65 30.14 43.17 -101.06
Tax 8.43 13.56 4.89 10.96 -23.52
Profit After Tax 24.22 16.09 25.25 32.21 -77.54
Adjusted EPS (Rs) 8.26 5.49 8.61 10.99 -26.45

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Net Sales 399.87 378.74 335.07 356.27 354.33
Total Expenditure 373.12 313.66 269.81 264.85 260.23
Operating Profit 26.75 65.08 65.26 91.42 94.1
Other Income 33.55 58.11 61.68 41.96 38.77
Interest 4.83 1.75 1.49 0.77 1.26
Depreciation 9.65 6.06 2.61 2.19 1.95
Exceptional Items -49.64 0 0 0 0
Profit Before Tax -3.82 115.38 122.84 130.42 129.66
Tax -0.1 12.02 37.65 29.52 36.48
Net Profit -3.72 103.36 85.19 100.9 93.18
Adjusted EPS (Rs.) -1.27 35.25 29.06 34.41 31.78

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity and Liabilities
Share Capital 12.34 12.34 12.34 12.34 12.34
Total Reserves 679.36 763.32 732.48 772.62 805.49
Borrowings 0 0 0 0 0
Other N/C liabilities 984 1007.77 716.25 696.83 724.89
Current liabilities 334.47 268.26 399.83 426.12 430.61
Total Liabilities 2010.17 2051.69 1860.9 1907.91 1973.33
Assets
Net Block 23.65 19.25 6.94 4.54 2.88
Capital WIP 0 0 0 0 0
Intangible WIP 0 0 0 0 0
Investments 0 0 0 0 0
Loans & Advances 1148.65 1240.75 903.63 870.18 910.78
Other N/C Assets 12 5.63 8.44 3.3 5.78
Current Assets 825.87 786.06 941.89 1029.89 1053.89
Total Assets 2010.17 2051.69 1860.9 1907.91 1973.33
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Profit from operations -3.82 115.38 122.84 130.42 129.66
Adjustment -5.64 -48.92 -56.75 -38.8 -33.76
Changes in Assets & Liabilities 66.72 -24 9.04 -0.76 -13.91
Tax Paid -18.59 2.34 38.27 -16.29 -35.26
Operating Cash Flow 38.67 44.8 113.4 74.57 46.73
Investing Cash Flow 87.04 -153.25 33.13 -3.31 17.63
Financing Cash Flow -35.63 -30.48 -120.99 -64.15 -63.93
Net Cash Flow 90.08 -138.93 25.54 7.11 0.43

Corporate Actions

Investors Details

PARTICULARS Sep 2025% Dec 2025% Mar 2026% Jun 2026% Sep 2026%
promoters 70.68 70.68 70.68 70.68 70.68
chryscapital fund x - - - - 10.32
two infinity partners - - - - 3.91
waverise investments limi... - - - - 56.45
novartis ag 70.68 70.68 70.68 70.68 -
PARTICULARS Sep 2025% Dec 2025% Mar 2026% Jun 2026% Sep 2026%
investors 29.32 29.32 29.32 29.32 29.32
atul limited 1.52 1.52 1.52 1.52 1.52
investor education and pr... - - 0.71 0.71 0.71
llp 0.31 0.42 0.25 0.26 0.03
investor education and pr... 0.69 0.72 - - -

Annual Reports

Title Link
Title Link
Annual Report 2026
Annual Report 2025
Annual Report 2024
Annual Report 2022
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
 No Credit reports exist for this company.Report us
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
Concall Q1FY27
Concall Q1FY27
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q1FY27

Company News

Evonile Pharma - Quaterly Results 5 Nov, 12:00 AM Evonile Pharma informs about revised integrated filing 4 Nov, 11:34 AM Novartis India - Quaterly Results 24 Jul, 12:00 AM Novartis India launches precision radiotherapy ‘Pluvicto’ for prostate cancer 15 Jun, 3:59 PM Novartis - Quaterly Results 13 May, 12:00 AM Novartis India informs about newspaper advertisements 17 Apr, 2:19 PM Novartis India informs about draft letter of offer 6 Mar, 5:07 PM Novartis - Quaterly Results 29 Jan, 12:00 AM Novartis India informs about newspaper advertisements 29 Oct, 5:03 PM Novartis - Quaterly Results 29 Oct, 12:00 AM Novartis India informs about integrated filing 28 Oct, 4:35 PM Novartis - Quaterly Results 29 Jul, 4:37 PM Novartis - Quaterly Results 29 Jul, 4:37 PM Novartis - Quaterly Results 29 Jul, 4:37 PM Novartis India informs about reappointment of director 10 May, 5:20 PM Novartis India informs about newspaper advertisements 10 May, 3:34 PM Novartis India informs about appointment of secretarial auditor 10 May, 9:57 AM Novartis - Quaterly Results 9 May, 7:12 PM Novartis - Quaterly Results 9 May, 7:12 PM Novartis - Quaterly Results 28 Jan, 1:18 PM Novartis - Quaterly Results 28 Jan, 1:18 PM Novartis - Quaterly Results 28 Jan, 1:18 PM Novartis - Quaterly Results 25 Oct, 1:13 PM Novartis - Quaterly Results 25 Oct, 1:13 PM Novartis - Quaterly Results 25 Oct, 1:13 PM Novartis - Quaterly Results 29 Jul, 1:30 PM Novartis - Quaterly Results 29 Jul, 1:30 PM Novartis - Quaterly Results 29 Jul, 1:30 PM Novartis India informs about loss of share certificate 4 Jul, 5:29 PM Novartis India informs about loss of share certificate 15 May, 5:06 PM Novartis India informs about board meeting outcome 10 May, 5:09 PM Novartis - Quaterly Results 10 May, 4:09 PM Novartis - Quaterly Results 10 May, 4:09 PM Novartis - Quaterly Results 10 May, 4:09 PM Novartis India informs about change in management 8 May, 5:23 PM Novartis India informs about details of loss of certificate 19 Mar, 2:50 PM Novartis India informs about loss of share certificate 28 Feb, 2:55 PM Novartis India informs about loss of share certificate 27 Feb, 11:40 AM Novartis India informs about loss of share certificate 17 Feb, 12:35 PM Novartis India informs about outcome of board meeting 17 Feb, 11:05 AM Novartis India informs about details of loss of certificate 9 Feb, 5:04 PM Novartis India informs about newspaper publication 27 Jan, 9:44 AM Novartis - Quaterly Results 25 Jan, 2:55 PM Novartis - Quaterly Results 25 Jan, 2:55 PM Novartis - Quaterly Results 25 Jan, 2:55 PM Novartis India informs about details of loss of certificate 6 Jan, 3:33 PM Novartis India informs about loss of share certificate 2 Jan, 2:20 PM Novartis India informs about issuance of duplicate share certificate 21 Dec, 4:52 PM Novartis India informs about details of loss of certificate 13 Dec, 12:53 PM Novartis India informs about details of loss of certificate 12 Dec, 4:58 PM

Evonile Pharma Stock Price Analysis and Quick Research Report. Is Evonile Pharma an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Evonile Pharma. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Evonile Pharma has a PE ratio of -1332.86578416762 which is low and comparatively undervalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Evonile Pharma has ROA of 4.8016% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Evonile Pharma has a Current ratio of 2.4474.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Evonile Pharma has a ROE of 11.6272%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Evonile Pharma has a Debt to Equity ratio of 0 which means that the company has low proportion of debt in its capital.

  • Sales growth: Evonile Pharma has reported revenue growth of -0.5445% which is poor in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Evonile Pharma for the current financial year is 26.5571642254396%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Evonile Pharma is Rs 0 and the yield is 0%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Evonile Pharma is Rs -1.1407. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Evonile Pharma in Ticker for free. Also, one can get the intrinsic value of Evonile Pharma by using Valuation Calculators, which are available with a Finology ONE subscription. 

Evonile Pharma FAQs

Q1. What is Evonile Pharma share price today?
Ans: The current share price of Evonile Pharma is Rs 1520.4.

Q2. What is the market capitalisation of Evonile Pharma?
Ans: Evonile Pharma has a market capitalisation of Rs 5318.15075316 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Evonile Pharma?
Ans: The PE ratio of Evonile Pharma is -1332.86578416762 and the P/B ratio of Evonile Pharma is 3.21051487967221, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Evonile Pharma share?
Ans: The 52-week high share price of Evonile Pharma is Rs 2178.4573526258, and the 52-week low share price of Evonile Pharma is Rs 799.418450631379.

Q5. Does Evonile Pharma pay dividends?
Ans: Currently, Evonile Pharma does not pay dividends. Dividend yield of Evonile Pharma is around 0%.

Q6. What are the face value and book value of Evonile Pharma shares?
Ans: The face value of Evonile Pharma shares is Rs 5, while the book value per share of Evonile Pharma is around Rs 473.5689. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Evonile Pharma?
Ans: Evonile Pharma has a total debt of Rs 0 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Evonile Pharma?
Ans: The ROE of Evonile Pharma is 11.6272% and ROCE of Evonile Pharma is 16.3365%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Evonile Pharma a good buy for the long term?
Ans: The Evonile Pharma long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Evonile Pharma undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Evonile Pharma appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Evonile Pharma’s financials?
Ans: You can review Evonile Pharma’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Evonile Pharma
X